Chief Executive Officer
Piers Whitehead has over 20 years of experience in the biopharma industry with a focus on commercial and business development functions in the fields of vaccines, immunology and public health. Over his career to date, he has led partnering transactions that generated over $450m in cash, played a key role in an IPO, led a complex acquisition and integration, led a multi-national, multi-product commercial function, co-authored US government grants and contracts with a headline value of greater than $1bn and executed multiple in-licenses from academia, the US Government and private companies. As Chief Business Officer of PaxVax, he led a successful process to sell a Priority Review Voucher; in-licensed the IP for the Company’s second commercial product; and designed and executed the acquisition and integration of vaccine assets from J&J/Crucell. Mr. Whitehead holds a BA with honours from Oxford University.
Todd Suscovich, PhD.
Chief Technical Officer
Dr. Todd Suscovich, Chief Technical Officer, leads the implementation and further development of the Systems Serology platform at SeromYx, expanding the use of this technology beyond the Infectious Disease space. Prior to joining SeromYx, his research broadly focused on how molecular events affect both the induction and regulation of the immune response during autoimmunity and infection and how these various pathways and underlying mechanisms can be manipulated to prevent/treat infection and disease. Since 2012, he has worked closely with Dr. Alter, leading the development and optimization of the Systems Serology platform, using this technology to identify antibody features and functions that are associated with protection from HIV infection. Recognizing the broad applicability of this platform in identifying correlates of protection in infection and vaccination beyond HIV, he spearheaded the adaptation and utilization of the Systems Serology technology across a broad range of globally relevant pathogens and diseases including tuberculosis, malaria, RSV, Ebola virus, Zika virus, and pertussis. Todd holds a Bachelor of Science in Molecular Biology from the University of Pittsburgh and a doctorate in Virology from Harvard Medical School.
Director, Scientific Development
Kaustuv Banerjee manages the SeromYx Systems assay portfolio extending applications to other therapeutic areas, such as, Oncology, Neurology, Allergy and Auto-immunity. In this role, he establishes collaborations with partners in the areas of mAb therapeutics development and immune profiling of patients for clinical trials. Prior to joining SeromYx Systems, spanning 8 years, Kaustuv managed the interface of techno-commercial consultative sales and services to academic and industrial customers, for two life science companies. Just prior to joining SeromYx he managed a multi-million US east coast commercial operation for Abcam’s custom antibody business, helping bio-pharma customers develop de novo antibody tools with applications in discovery, translational, diagnostic and clinical development programs. For the MilliporeSigma Immunoassay Platform Solutions (IPS) flow cytometry and protein multiplexing instrumentation and kits business, Kaustuv served as the field technical liaison in pre- and post-sales operations connecting US and Canadian customers with IPS solutions. His success in these techno-commercial scenarios is bolstered by an experienced research career, in a discovery role in vaccines industry at Novartis Vaccines and Diagnostics and in an academic setting at the Weill Cornell Medical College. Kaustuv holds a degree in the Veterinary Sciences and trained as a cellular immunologist at the College of Veterinary Medicine, University of Tennessee, Knoxville, receiving his Ph.D. in 2004.
Director of Operations
Briana Dougherty, Director of Operations, oversees multiple areas at SeromYx including Facilities, Ordering and Procurement, Quality and IT. In this role, she has implemented many internal processes and procedures and led SeromYx’s GCLP accreditation process. Prior to joining SeromYx, Briana has spent over 10 years working at multiple CAP/CLIA certified molecular diagnostic testing companies in laboratory operations and quality control. Initially starting out as a laboratory technologist, Briana spent over 5 years in quality control before moving into laboratory operations and facility management. Briana holds a B.S. with honors in Biotechnology from Worcester Polytechnic Institute.
Galit Alter, PhD.
Chief Scientific Officer
Galit Alter received her PhD in experimental medicine from McGill University, and is currently a Professor in Medicine at Harvard Medical School and a faculty member at the Ragon Institute of MGH, MIT, and Harvard. Her research interests lie at the intersection of the innate immune response and the adaptive humoral immune response, with a focus on defining the role of innate immune recruiting antibodies in providing specificity to the innate immune system to kill virally infected cells. In this capacity, Dr. Alter has developed a suite of antibody profiling assays, collectively Systems Serology, that aim at gaining a deeper appreciation of the correlates of humoral immune activity against HIV and beyond. Galit serves as SeromYx CSO on a part-time consulting basis.